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Ankylosing spondylitis patients display altered
dendritic cell and T cell populations that implicate
pathogenic roles for the IL-23 cytokine axis and
intestinal inflammation
Pamela B. Wright1, Anne McEntegart2, David McCarey2, Iain B. McInnes1,
Stefan Siebert1 and Simon W. F. Milling1
Abstract
Objective. AS is a systemic inflammatory disease of the SpA family. Polymorphisms at loci including
HLA-B27, IL-23R and ERAP-1 directly implicate immune mechanisms in AS pathogenesis. Previously,
in an SpA model, we identified HLA-B27mediated effects on dendritic cells that promoted disease-
associated Th17 cells. Here we extend these studies to AS patients using deep immunophenotyping of
candidate pathogenic cell populations. The aim of our study was to functionally characterize the immune
populations mediating AS pathology.
Methods. Using 11-parameter flow cytometry, we characterized the phenotype and functions of lympho-
cyte and myeloid cells from peripheral blood, and the synovial phenotype of AS patients and age-matched
healthy controls.
Results. Significantly fewer circulating CD1c-expressing dendritic cells were observed in AS patients,
offset by an increase in CD14 CD16+ mononuclear cells. Ex vivo functional analysis revealed that this
latter population induced CCR6 expression and promoted secretion of IL-1b and IL-6 when co-cultured
with naive CD4+ T cells. Additionally, systemic inflammation in AS patients significantly correlated with
increased proportions of activated CCR9+ CD4+ T cells.
Conclusion. CD14 CD16+ mononuclear cells may contribute to AS by promoting Th17 responses, and
antigen-presenting cells of mucosal origin are likely to contribute to systemic inflammation in AS.
Key words: dendritic cells, CD4+ T cells, ankylosing spondylitis, inflammation, CD14 CD16+ mononuclear
cells.
Rheumatology key messages
. The AS immunological signature consists of altered myeloid (CD1c+ : CD16+) and lymphocyte (CCR6 : CXCR3)
profiles.
. CD14 CD16+ mononuclear cells may support Th17-mediated AS disease pathology through CCR6, IL-1b and
IL-6 induction.
. The intestinal environment may drive systemic inflammation in AS patients in a CCR9-dependent manner.
Introduction
AS is a chronic arthropathy of the axial and peripheral
skeleton, characterized by inflammation and abnormal
bone and entheseal remodelling. AS is recognized as
the prototypic disease of a larger SpA group of condi-
tions that share genetic, pathophysiological and clinical
features. Although transformed by the introduction of
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TNF inhibitors a decade ago, current therapeutics re-
main inadequate for a substantial proportion of patients,
offering a compelling case for improved pathophysiolo-
gical discovery. Large genome-wide association studies
have recently contributed several novel loci and hence
novel candidate pathways in this regard. There is
particular interest in the confirmed associations with IL-
23R, ERAP1 and STAT3 [13]. Taken together with the
provisional clinical benefit accrued upon inhibition of
the IL-17A pathway in clinical trials in AS patients [4],
this suggests that novel immune-mediated path-
ways beyond TNF may now be formally implicated in
pathogenesis.
Prior mechanistic studies have relied heavily on data
generated using animal models. Experiments using trans-
genic rats overexpressing the human HLA-B27 and
b2-microglobulin genes (B27-TG) have, for instance,
implicated CD4+ T cells [5, 6], myeloid cells [7, 8] and
endoplasmic reticulum (ER) stress [9] in the development
of SpA. There are as yet few data informing analogous
mechanisms operating in patients. Given that HLA-B27
is an MHC class I molecule, it is intriguing that disease
in B27-TG rats occurs independently of CD8+ T cells [6].
Moreover CD4+ T cells expanded in AS patient peripheral
blood are enriched for a population of Th17 phenotype
[1012]. Dendritic cells (DCs), which regulate T cell
responses, have been strongly implicated in SpA patho-
genesis in B27-TG rats [7, 8, 13]. Parallel studies in pa-
tients are, however, rare. Most have heretofore focused
on cells generated from monocytes following ex vivo cul-
ture with GM-CSF and IL-4 (mo-DCs) [14]. These express
reduced surface MHC II expression compared with cells
from healthy individuals, but no alteration in production of
IL-23 or other cytokines [15, 16]. On the other hand,
in vitro studies do suggest that ER stress of DCs could
lead to excessive IL-23 production [17], and as such they
are intriguing candidate cells in initiating this effector path-
way. In this regard, however, the relevance of data
generated using cultured monocytes to DC biology is un-
clear [18]. We consider it critical now to determine the
contributions of bone fide DCs and other myeloid lineages
to AS pathogenesis.
Our previous analyses revealed a systemic deficiency in
a specific DC population in B27-TG rats, which in turn
promoted elaboration of Th17 responses [19]. Because
this cytokine axis may be associated with AS pathology,
we hypothesized that myeloid populations could be simi-
larly altered in AS patients. Accordingly, we performed
deep phenotyping of blood and SF leucocyte populations
and now show that the frequency of circulating CD1c+
DCs is diminished in AS patients. Conversely, proportions
of CD14 CD16+ mononuclear cells are elevated and
functionally promote CCR6 induction and IL-6 and IL-1b
secretion following T cell interaction. Furthermore, we
identify a correlation between systemic inflammation and
a gut-homing phenotype among T cells from AS patients.
Thus, we provide novel insight into the pathways that can
promote chronic inflammation mediated through the Th17
axis.
Materials and methods
Patients
AS patients meeting the modified New York criteria [20]
were recruited from the Glasgow Royal Infirmary rheuma-
tology clinic between March 2011 and June 2013.
Informed, written consent was obtained from all study
participants according to the Declaration of Helsinki.
Ethical approval for the study was awarded by the West
of Scotland Research Ethics Service (Institute of Infection,
Immunity and Inflammation Research Tissue Bank, REC:
11/S0704/7). Consenting age- and sex-matched healthy
controls (HCs) were recruited under ethics approved by
the College of Medical, Veterinary, and Life Sciences
Ethics Committee, University of Glasgow (Project
#2013007). Patient clinical features are outlined in supple-
mentary Table S1, available at Rheumatology Online.
Reagents
Cells were cultured in RPMI 1640 supplemented with 10%
fetal calf serum, 100 U/ml penicillin, 100mg/ml strepto-
mycin, 2 mM L-glutamine and 50 mM 2-mercaptoethanol
(complete medium).
Peripheral blood mononuclear cell isolation
Isolation of peripheral blood mononuclear cells was per-
formed over a Histopaque1077 gradient. Following cen-
trifugation, the peripheral blood mononuclear cell layer
was harvested.
Antibodies
Directly conjugated or biotin-labelled antibodies targeting
CD3 (UCHT-1), CD4 (OKT4), CD14 (M5E2), CD15 (W6D3),
CD16 (3G8), CD19 (HIB19), CD25 (BC96), CD45RA
(HI100), CD56 (MEM-188), HLA-DR (L243), TcRab (IP26)
and CXCR3 (GO25H7) were from Biolegend (San Diego,
CA, USA). Antibodies targeting CCR9 (248621) and
CCR10 (314305) were purchased from R&D systems
(Minneapolis, MN, USA). CD1c (AD5-8E7) and anti-SLAN
(M-DC8, DD-1) antibodies were from Miltenyi Biotec
(Auburn, CA, USA). CD11c (B-ly6), CD141 (1A4), CCR6
(11A9) and CCR4 (1G1) antibodies were purchased from
BD Biosciences (Oxford, UK).
Flow cytometry
Following Fc receptor inhibition (eBioscience, San Diego,
CA, USA), staining was performed in PBS with 2% fetal
calf serum and 2 mM EDTA. Where biotin-conjugated anti-
bodies were used, a streptavidin step was performed.
Samples were acquired using LSR II (BD Biosciences) or
MACSQuant (Miltenyi Biotec) flow cytometers, or purified
using a FACSAria cell sorter (BD Biosciences). Data were
analysed using FlowJo software (version 9.2; Tree Star,
Ashland, OR, USA).
Naive CD4+ T cell isolation
Naive CD4+ T cells were isolated from peripheral blood
mononuclear cells using a naive CD4+ T cell isolation kit
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(Miltenyi Biotec). Cells were stained with carboxyfluores-
cein succinimidyl ester (CFSE: 5 mM).
Mixed leucocyte reaction
Myeloid populations were resuspended in complete
medium and co-cultured with CFSE-labelled allogeneic
naive CD4+ T cells for 5 days. Supernatants were har-
vested and proliferation assessed through CFSE dilution.
RNA extraction
A MicroRNA kit (Qiagen, Venlo, Netherlands) was used for
RNA extraction. Genomic DNA was removed using an
RNase-free DNase kit (Qiagen). cDNA was generated
using a Superscript First Strand Kit (Invitrogen).
Real-time quantitative PCR
Gene expression was measured using the Brilliant III Ultra
Fast SYBR GREEN qRT-PCR Master Mix (Agilent
Technologies, Santa Clara, CA, USA). Reactions were
analysed using a 7500 Fast Real-Time PCR System ma-
chine (Applied Biosystems, Foster City, CA, USA). Primers
used were TATA-binding protein (TBP) : forward AGACCT
TCCTGTTTACCCTTG, reverse TAGCTGTGGGTGACTGC
TTGG; ATF4: forward GACCACGTTGGATGACACTTG, re-
verse GGGAAGAGGTTGTAAGAAGGTG; PERK: forward T
GCCTGGCTCGAAGCACCAC, reverse TGGTGCATCCAT
TGGGCTAGGA; EIF2a: forward GCTCTTGACAGTCCGA
GGAT, reverse CATTGCCCCAGGCAAACAAG; unspliced
XBP-1: forward AGACAGCGCTTGGGGATGGAT, reverse
CCTGCTGCAGAGGTGCACGTAG; spliced XBP-1: for-
ward AGACAGCGCTTGGGGATGGAT, reverse CCTGCA
CCTGCTGCGGACTC; ATF6: forward TCAGACAGTACC
AACGCTTATGC, reverse GTTGTACCACAGTAGGCT
GAGA; and Bip: forward TGCTTGATGTATGTCCCCTTA,
reverse CCTTGTCTTCAGCTGTCACT. Expression levels
were normalized to TBP. Results were presented as
2Ct.
Cytokine detection
Cytokines IL-1b, IL-4, IL-5, IL-6, IL-10, IL-17A, GM-CSF,
IFNg and TNFa were detected using a custom-made
Luminex assay (R&D systems), using the BioPlex 200
system (Bio-Rad, Hercules, CA, USA). Flt3L, IL-23p19
and IL-12p70 were detected by ELISA (R&D systems).
Plates were read using an MRX microplate reader (Dyn-
ex technologies, Chantilly, VA, USA).
Statistics
Results were presented as +S.D. Data were analysed by
Student’s t-test or MannWhitney U test, followed by a
Bonferroni post-test using GraphPad prism (San Diego,
CA, USA). Linear regression, KruskalWallis Spearman
correlative tests were performed with Dunn multiple com-
parisons post-tests. Values of P< 0.05 were considered
statistically significant.
Results
The CD4+ T cell CCR6/CXCR3 axis is altered in
AS patients
T cells belonging to the Th17 lineage have been asso-
ciated with disease pathogenesis in B27-TG rats [9, 19]
and AS patients [1012]. We performed detailed immuno-
phenotyping of the circulating CD4+ T cell profile in AS
through quantification of T cell populations and their ef-
fector status. The latter aspect was determined through
examination of chemokine receptor expression (com-
monly used surrogate markers of T helper cell polariza-
tion) [21, 22]. We first segregated four CD4+ TcRab+
populations based on CD25 and CD45RA expression
(Fig. 1A), namely naive (CD45RA+ CD25), memory
(CD45RA CD25), activated (CD45RA CD25int) pheno-
types and Tregs (CD45RA CD25hi). All Tregs expressed
FoxP3 (Fig. 1A). Enumeration of CD4+ T cell subsets
revealed no differences between AS patients and HCs
(Fig. 1B). Elevated levels of CCR6 and reduced CXCR3
expression were observed on activated (CD25int) CD4+
AS patient T cells (Fig. 1C and D). CXCR3 expression
was also reduced on AS CD4+ memory T cells (Fig. 1D).
CCR9, CCR4 and CCR10 were not differentially ex-
pressed on HC and AS patient CD4+ T cell populations
(Fig. 1E and supplementary Fig. S1, available at
Rheumatology Online). These data highlight differences
in the chemokine receptor profile of circulating CD4+
T cells in AS patients, with a propensity towards elevated
proportions of CCR6-expressing effector populations.
AS patient plasma contains elevated levels of
Th17-associated cytokines
To understand how the balance of T helper subsets might
be regulated in AS patients, we examined the plasma
cytokine and growth factor profiles in our cohort. We
observed a modest increase in TNFa levels in AS patient
plasma (Fig. 2A). IL-1b levels were similar to those of con-
trols (Fig. 2B). Assessment of several plasma Th-asso-
ciated cytokines revealed a significant reduction in
plasma IL-4 in AS patients, while IL-10 and IFNg levels
resembled those of HCs (Fig. 2C). In contrast, there was
significant upregulation in the circulating levels of the
Th17-associated cytokines IL-6 and IL-23p19, but no in-
crease in IL-17A itself (Fig. 2C). Thus, the cytokine milieu
in AS patients is skewed towards the Th-17/IL-23
axis. Interestingly, Flt3L, a myeloid haematopoietic
growth factor, was significantly upregulated in AS patient
plasma compared with HCs (Fig. 2D).
The proportion of circulating CD16+ mononuclear
cells increased in AS
Data from our laboratory support a relationship between
systemic myeloid dysregulation and AS/SpA; we previ-
ously demonstrated that B27-TG rats lack CD103+
CD172alo DCs [19], while Flt3L was significantly upregu-
lated in AS patients (Fig. 2D). Thorough examination of
myeloid populations may elucidate their involvement in
promoting the aberrant T cell phenotypes observed in
www.rheumatology.oxfordjournals.org 3
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our patient cohort. To our knowledge, no prior study has
directly addressed this question ex vivo without prior cell
expansion in culture. Lineage CD14 CD11c+ HLA-DR+
cells were subdivided into three myeloid populations
based on their differential expression of CD141 and
CD16 (supplementary Fig. S2A and B, available at
Rheumatology Online). The CD141 CD16 population
expresses CD1c (data not shown) and thus represents
CD1c+ DCs. The CD141 CD16+ population [23], collect-
ively termed CD14 CD16+ mononuclear cells, was
heterogeneous for 6-Sulpho LacNAc (SLAN) (M-DC8)
and thus contained CD14 CD16+ SLAN and SLAN+
subsets (supplementary Fig. S2A, available at
Rheumatology Online). No difference was observed in
the proportion of total DCs (CD1c+ and CD141+ DCs) be-
tween HCs and AS patients (Fig. 3A). Unfortunately, our
study was insufficiently powered, with too few HLA-B27+
HCs and HLA-B27 AS patients to examine the influence
of HLA-B27 on immunological disease parameters
(Fig. 3A). Analysis of plasmacytoid DCs (HLA-DR+
FIG. 1 Expression of CCR6 and CXCR3 on circulating CD4+ T cell subsets
(A) CD25 and CD45RA define four circulating CD4+ T cell populations. FOXP3 expression on total CD25+ cells.
(B) Quantification of naive (CD45RA+), memory (CD25), activated (CD25int) and regulatory (CD25hi) T cells in HCs
(n= 14, empty bars) and AS patients (n= 27, filled bars). CCR6 (C), CXCR3 (D) and CCR9 (E) expression on CD4+
T cell subsets [HCs (empty circles), n= 713; AS patients (filled circles), n= 1326]. Each dot represents one
individual. *P< 0.05, MannWhitney test performed for CXCR3 expression on CD25 T cells, otherwise unpaired
Student’s tests were performed. Error bars show mean + S.D.
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CD123+ CD304+) revealed no significant difference be-
tween HCs and AS patients (supplementary Fig. S2C,
available at Rheumatology Online). We observed no dis-
parities in the frequencies of CD141+ DCs in AS patients
(Fig. 3B). However, analogous to that population we pre-
dicted would be deficient from our B27-TG experiments
[19], analysis of clinical data (supplementary Table S1,
available at Rheumatology Online) revealed a significant
correlation between increased proportions of CD141+
DCs and greater disease severity when assessed by
BASDAI (disease activity) but not by BASFI (for func-
tional limitation see supplementary Fig. S3, available at
Rheumatology Online).
Unexpectedly, we observed a significant proportional
reduction in CD1c+ DCs in AS patients (Fig. 3B). This find-
ing was offset by increased frequencies of total CD14
CD16+ mononuclear cells in AS patients (P= 0.0552), des-
pite no proportional differences in SLAN-expressing
subsets (Fig. 3C). Comparison of the major blood myeloid
populations revealed a significant shift from CD1c+
DCs towards CD14 CD16+ mononuclear cells in AS pa-
tients (Fig. 3D). The unfolded protein response (UPR)
induced within myeloid cells as a consequence of ER
stress initiated through HLA-B27 misfolding, is thought
to contribute to disease pathogenesis in B27-TG rats
[79]. Despite the observed myeloid dysregulation
(Fig. 3B and C), we failed to detect UPR induction in AS
patient CD1c+ DCs and CD14 CD16+ mononuclear cells
(Fig. 3E). Upregulation of BiP expression was observed
within CD14 CD16+ mononuclear cells (Fig. 3E).
Myeloid populations can be identified in AS
patient SF
A presumed pathophysiological destination of circulating
cells is the articular compartment. As tissue is not readily
available from the spine, we analysed the immune cell
milieu of four AS patient SF samples. Analysis of lineage
CD11c+ MHC II+ cells revealed four myeloid populations:
CD14+ CD16 monocytes, CD14+ CD16+ monocytes and
two DC populations (CD141+ and CD1c+; Fig. 4A). In con-
trast to peripheral blood (Fig. 3C and supplementary Fig.
S2B, available at Rheumatology Online), the CD14
CD16+ SLAN+ and SLAN mononuclear cell subsets
were absent from AS SF (Fig. 4A and B). High levels of
CCR4 and CCR6 expression were observed on SF CD3+
CD4+ T cells (Fig. 4C), and most CD4+ CD25hi cells co-
expressed both chemokine receptors (Fig. 4C). To identify
inflammatory mediators driving joint pathology, the cyto-
kine milieu from matched AS patient SF and blood sam-
ples was analysed. IL-10, IL-17A, TNFa and Flt3L were not
differentially expressed between plasma and SF (Fig. 4D).
FIG. 2 Systemic cytokine profile of AS patients
Cytokine and growth factor levels were determined by Luminex or ELISA for HCs (empty circles) and AS patients
(filled circles). Levels of TNFa (A) and IL-1b (B) in HC (n= 2425) and AS patient (n= 38) plasma. (C) Detection of Th cell-
associated cytokines IL-4, IL-10, IFNg, IL-6, IL-17A and IL-23p19 within HC (n= 2324) and AS patient (n= 38) plasma.
(D) Amount of plasma Flt3L in HCs (n= 24) and AS patients (n= 38). Statistical analyses were performed between HCs
and AS patients for each parameter. *P< 0.05, **P< 0.01, ***P< 0.001 using MannWhitney tests.
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In contrast, IL-6 concentrations were dramatically
increased within AS SF (Fig. 4E).
DCT cell interactions promote Th17-like immune
responses
Cognate interactions between antigen-presenting cells,
principally DCs, and T cells are central to the regulation
of immune responses. To investigate blood myeloid cell
function, we assessed their ability to stimulate prolifer-
ation of naive allogeneic CD4+ T cells. HC and AS patient
myeloid cells induced similar CD4+ T cell proliferation at all
DC:T cell ratios (Fig. 5A). DCs have a greater capacity to
induce naive T cell proliferation than blood mono-
cytes (supplementary Fig. S4, available at Rheumatology
Online). Supernatant analysis from these co-cultures re-
vealed no difference in IL-1b and IL-6 production between
HCs and AS patients (Fig. 5B). CD14 CD16+ mononu-
clear cellCD4+ T cell co-cultures consistently secreted
the highest levels of IL-1b and IL-6 (Fig. 5B). The Th-asso-
ciated cytokines IFNg and IL-17A were also examined;
however, no significant differences were observed (data
not shown). Overall, interactions between CD14 CD16+
mononuclear cells and T cells promote secretion of the
Th17-associated cytokines IL-1b and IL-6.
FIG. 3 Circulating myeloid profile of AS patients
(A) Enumeration of total circulating HC (n= 29) and AS patient (n= 43) DCs. Grey dots indicate HLA-B27+ HCs and HLA-
B27 AS patients where appropriate. CD141+ and CD1c+ DCs (B), total CD16+ and SLAN+ CD16+ mononuclear cells
(C) as a proportion of LIN (CD3/CD15/CD19/CD56) CD14 CD11c+ HLA-DR+ cells in HCs (n= 930) and AS patients
(n= 1143). (D) Ratio of CD16+ mononuclear cells:CD1c+ DCs in HCs (n= 29) and AS patients (n= 43). (E) ER stress gene
expression in FACS-purified HC (n= 4) and AS patient (n= 3) myeloid cells, relative to TATA-binding protein (TBP) using
the 2Ct method with the HC population equal to 1 (arbitrary units. *P< 0.05, MannWhitney test or two-way ANOVA.
Error bars show ± S.D.
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CCR6 is often used as a surrogate marker for Th17 cells
[22], although not all CCR6+ cells secrete IL-17A (data not
shown). Given that published data implicate Th17 cell in-
volvement in AS pathogenesis [1012], and the elevated
CCR6 expression on AS patient CD4+-activated T cells
observed by us, we explored whether these phenomena
could arise from altered DCT cell interactions. We per-
formed mixed leucocyte reactions and assessed CCR6
expression on proliferating CD4+ T cells (Fig. 5C). Blood
DCs and CD14 CD16+ mononuclear cells from AS
patients and HCs all induced CCR6 on interacting
T cells, to similar levels (Fig. 5D).
Disease pathogenesis linked to CCR6+ and CCR9+
CD4+ T cells
Finally, to further explore our data relative to clinical
phenotypes, we evaluated the relationships between im-
munological and clinical parameters. We observed that
increased frequencies of CCR6+ Tregs (CD25hi) were
significantly associated with elevated disease severity,
FIG. 4 Immunological milieu of AS SF
(A) Live, single LIN (CD3/CD15/CD19/CD56) CD11c+ HLA-DR+ cells were divided into three myeloid subsets: CD14+
CD16 monocytes, CD14+ CD16+ monocytes and CD14 CD16 cells. The CD14 CD16 subset contained SF
DCs—CD141+ and CD1c+ populations. (B) SLAN expression on total live LIN CD14 CD11c+ HLA-DR+ cells, compared
with isotype (shaded grey). (C) CCR9, CCR10, CCR4 and CCR6 expression on AS patient (n= 1) CD3+ CD4+ SF T
cells. AS patient (n= 2) concentrations of IL-10, IL-17A, TNFa, Flt3L (D) and IL-6 (E) in matched plasma (empty) and
SF (filled).
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assessed by both BASMI and BASFI (Fig. 6A). Although
similar relationships were observed between increasing
frequencies of CCR6+ activated T cells (CD25int) and
BASMI and BASFI, these did not reach significance
(Fig. 6A). Furthermore, we observed significant correl-
ations between increased proportions of CCR9+ CD4+
activated T cells and elevated ESR and CRP scores
(Fig. 6B).
Discussion
The genetic link between HLA-B27 and AS was identified
more than 40 years ago, yet the mechanisms underpin-
ning this association remain elusive. Studies of B27-TG
rats indicate involvement of myeloid populations
and CD4+ T cells (specifically the Th17 lineage) in SpA
pathology [59, 19, 24]. Parallel human studies have
highlighted involvement of the Th17/IL-23 pathway in AS
[1, 2, 12, 25]. Despite this, evidence for IL-17secreting T
cells in inflamed, extra-articular tissues is limited [2628].
Furthermore, examination of the critical myeloid popula-
tions has only been performed indirectly, using in vitro-
generated mo-DCs [15, 16]. These cultures do not
recapitulate the diverse populations found in vivo. We
have performed the first detailed phenotypic and func-
tional analyses of freshly isolated myeloid populations in
AS. We have not, however, performed these analyses
using samples from patients with other inflammatory dis-
eases. Such comparisons have previously been shown to
be valuable [29, 30]. Further studies are therefore required
to establish whether our immunological observations are
unique to AS pathophysiology. Additionally, the majority of
FIG. 5 Functional assessment of DC : T cell interactions in AS
(A) CD4+ T cell proliferation assessed by mixed leucocyte reaction (MLR) with indicated myeloid populations. (B) IL-1b
and IL-6 secretion following MLR. (C) Representative plot depicting CCR6 induction on proliferating CD4+ T cells fol-
lowing HC CD1c+ DC co-culture. (D) Quantification of CCR6 expression on proliferating CD4+ T cells following MLR with
individual myeloid subsets. For analysis, 410 HCs and 615 AS patients were used. Dotted line at 1.078 equates to level
of CCR6 expression on naive CD4+ T cells. **P< 0.01 and ***P< 0.001. MannWhitney test or two-way ANOVA (B) were
performed. Error bars show ± S.D.
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our patients presented with long-standing disease; if
samples were available it would be fascinating to repeat
these studies using patients in the earliest stages of
disease.
Significantly, our analyses support reports of a systemic
imbalance in circulating CD4+ T cell subsets in AS,
favouring cells of the Th17 lineage. We identified this im-
balance using CCR6 and CXCR3 as surrogate markers of
FIG. 6 Immunological parameter correlations with disease progression and inflammation in AS
(A) Correlations between AS patient (n= 14) CCR6-expressing CD4 +CD25hi T cells (Tregs; Top) and CCR6+ CD25int T
cells (activated; bottom) with BASMI (left) and BASFI (right) clinical scores. (B) ESR and CRP correlations with AS patient
(n= 16) CCR9+ CD4+ CD25int (activated) cell frequencies. Each dot represents one individual. Analyses were performed
and assessed using linear regression and the KruskalWallis Spearman correlative statistical tests (r), using the Dunn
multiple comparisons post-test. *P< 0.05, **P< 0.01 and ***P< 0.001.
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Th17 and Th1 differentiation, respectively [21, 22]. The
elevations we observe in circulating levels of the
Th17-associated cytokines IL-6 and IL-23 may promote
induction and survival of these Th17-like cells in vivo
[31, 32]. IL-23 has also been shown to directly drive
SpA-associated pathology in animal models, and has
been associated with human disease [26, 33, 34]. Our
data support these observations, implicating involvement
of CCR6+/Th17-associated CD4+ lymphocytes and the
IL-23 cytokine axis in AS pathogenesis [9, 19, 25].
We previously identified a systemic deficiency in the
CD103+ CD172alo tolerogenic DC population in B27-TG
rats [19]. We hypothesized that the analogous human
subset, CD141+ DCs, would be absent or depleted in
AS patients. However, we observed no differences in
the frequencies of circulating CD141+ DCs between AS
patients and HCs. In fact, elevated proportions of circulat-
ing CD141+ DCs were weakly associated with increased
disease severity. Thus, unlike in B27-TG rats, a loss of this
DC subset does not appear to drive human disease.
Hence, several immunological processes driving human
AS appear to differ from those driving SpA-like symptoms
in B27-TG rats. In contrast, we observed a significant re-
duction in the frequency of the largest blood DC popula-
tion, CD1c+ DCs, in AS patients. It should be noted that
there was a 15-year difference between the average ages
of the HC and AS patient cohorts. We consider it unlikely
that this disparity caused the observed differences be-
tween our HC and AS patient populations because our
analyses did not detect any influence of donor age on
the number or frequency of any DC population in our co-
horts (data not shown). In myeloid cells of B27-TG rats,
the UPR, driven by misfolded HLA-B27 molecules, in-
duces release of pro-inflammatory cytokines and cell
death [9, 35, 36]. However, we could detect no evidence
for UPR activation in circulating CD1c+ DCs and CD14
CD16+ mononuclear cells from AS patients. Our results
thus support previous observations using more
heterogeneous cell preparations from blood or intestine
[3741] and implicate involvement of alternative disease-
associated immunopathogenic mechanisms. If HLA-
B27induced UPR induction is indeed the force driving
AS, future investigations will need to carefully examine
whether any tissue-resident cell populations show evi-
dence of ER stress or UPR activation.
Accompanying the reduced frequency of blood CD1c+
DCs was an increase in the heterogeneous CD14 CD16+
mononuclear cell population. This population contains
both patrolling CD16+ blood monocytes [23] and M-
DC8/SLAN+ DCs [42, 43]. To understand the functional
consequences of these changes, we assessed the ability
of these myeloid populations to activate naive T cells. On
a per-cell basis, no differences were observed between
AS patient and HC myeloid cells; CD14 CD16+ mononu-
clear cells promoted secretion of the Th17-associated
cytokines IL-1b and IL-6 and were capable of inducing
CCR6 expression on interacting T cells. Consequently,
the observed shift towards the CD14 CD16+ myeloid
population in AS patients may contribute to the induction
of the pathology-associated Th17 response. Of note, SpA
patient CD1c+ DCs express elevated levels of CD1d,
which was shown to have immunoregulatory properties
[44]. Our observation, that there is a reduction in the fre-
quency of circulating CD1c+ DCs in AS patients, contrib-
utes to the evidence suggesting that myeloid cells may be
involved with disease progression. To test this connec-
tion, further studies are required to address the role of
DCs in driving disease at sites of ongoing inflammation
in AS.
Analyses of the more readily available cells in blood
may not accurately reflect immunological processes
occurring in disease-affected tissues. Examination of
tissue populations can therefore be helpful in elucidating
pathogenic mechanisms. SF samples from peripheral
joints, although not necessarily representative of AS
spinal or musculoskeletal pathophysiology, remain an
important resource for characterizing potential tissue ef-
fector populations. We identified CD1c+ DCs in AS SF, as
previously observed in RA SF [45]. Additionally, we iden-
tified a high frequency of CD141+ DCs in AS SF. These
SF-resident DCs may perpetuate disease by driving local
T cell responses. However, because these results were
generated using very limited numbers of samples, further
phenotypic and functional analyses must be performed to
better understand the role of the immune populations
residing within the SF. Of note, CD14 CD16+ mononu-
clear cells were completely absent from AS SF, indicating
that they do not act locally to drive peripheral joint disease
in AS. CD14 CD16+ SLAN+ cells have, however, been
identified in inflamed extra-articular tissues, including
tonsil and psoriatic skin [46, 47]. Together with our results,
these data suggest that extra-articular CD14 CD16+ cells
in lymphoid or other peripheral tissues may contribute to
AS pathogenesis.
To understand how immunological changes may con-
tribute to disease development, we must consider how
these differences relate to patient clinical characteristics.
In our cohort, it was clear that CCR6+ Tregs were more
frequent in patients with the highest disease scores.
From this correlation we infer that in AS patients, CCR6-
expressing Tregs may be induced in an attempt to sup-
press pathology. Further investigation is clearly required
to accurately assess whether this population has any
effect on disease progression.
Interestingly, our data indicate a relationship between
intestinal immune responses and systemic inflammation in
AS; elevated ESR and CRP values correlate with higher
proportions of circulating CCR9-expressing activated
T cells. CCR9 is induced on T cells activated in intestinal
lymphoid tissues [48]. Thus, this correlation indicates that
systemic inflammation in AS is associated with intestinal
activation of T cells. This is potentially extremely import-
ant, given the absence of inflammation from B27-TG rats
housed under germ-free conditions, and the fact that
50% of AS patients show evidence of subclinical intes-
tinal inflammation [49, 50]. Together, these results indicate
that antigen-presenting cells of intestinal origin may play a
central role in driving systemic inflammation in AS
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patients. Given this association between systemic inflam-
mation and the intestinal immune response, it is important
to understand the impact of peripheral disease manifest-
ations, especially signs of IBD, on disease and immuno-
logical parameters. Unfortunately, our study was not
sufficiently powered (containing too few patients with
IBD) to address this directly.
In summary, we have performed extensive immunophe-
notyping of AS patients and have identified disease-
associated alterations in circulating T lymphocytes and
myeloid populations. Specifically, elevated proportions
of CD14 CD16+ mononuclear cells, capable of inducing
CCR6-expressing T cells and IL-1b and IL-6 production,
may contribute to the Th17 immune responses that are
associated with AS. Furthermore, intestinal immune re-
sponses appear to contribute to systemic inflammation
in AS patients, implicating loss of intestinal homeostasis
as an important factor driving disease. Together, these
observations enhance our understanding of the pathogen-
esis of AS, and support the idea that aberrant T cell re-
sponses and intestinal inflammation contribute to the
pathogenesis of this disease.
Supplementary data
Supplementary data are available at Rheumatology
Online.
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